Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. Their approach is centered on harnessing the body's natural regulatory mechanisms to stabilize the immune response, specifically through enhanced expression of microRNA-124. Their lead drug candidate, obefazimod, is an orally administered, once-daily therapy that has shown promising results in clinical trials for ulcerative colitis and rheumatoid arthritis. It is currently in Phase 3 trials for ulcerative colitis.

Abivax is headquartered in Paris, France, with US headquarters in the greater Boston area. They have a global presence with clinical trials conducted worldwide. They are actively building their team with local-market expertise and anticipate initial commercialization of obefazimod in the US. While their primary focus is on inflammatory bowel diseases, they are also exploring the potential of obefazimod for other inflammatory indications and developing a proprietary chemical library to discover new drug candidates.

Abivax is a clinical-stage biotechnology company committed to developing transformative treatments for patients with chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. Their primary focus is on enhancing the expression of microRNA-124, a naturally occurring molecule that plays a key role in regulating the immune response. Through this approach, they aim to stabilize the immune system and create more effective and long-lasting treatments for diseases such as ulcerative colitis and Crohn's disease.

Abivax fosters a culture of innovation and collaboration, focused on developing transformative treatments for patients with chronic inflammatory diseases. The company values scientific rigor, patient-centricity, and a commitment to exploring revolutionary science. Abivax's global headquarters in Paris and US headquarters in the greater Boston area, coupled with a diverse and experienced leadership team, demonstrate a commitment to inclusivity and a global reach.